Bis(acetylacetonato)-oxidovanadium(IV) inhibits isoproterenol-induced lipolysis in insulin-resistant 3T3-L1 adipocytes by reducing phosphorylation of perilipin and hormone-sensitive lipase

doi:10.5246/jcps.2016.11.090

Journal of Chinese Pharmaceutical Sciences ›› 2016, Vol. 25 ›› Issue (11): 814-820.DOI: 10.5246/jcps.2016.11.090

• Original articles • Previous Articles Next Articles

Bis(acetylacetonato)-oxidovanadium(IV) inhibits isoproterenol-induced lipolysis in insulin-resistant 3T3-L1 adipocytes by reducing phosphorylation of perilipin and hormone-sensitive lipase

Xia Hu, Jingcheng Liu, You Yu, Weixia Bian, Xiaogai Yang^*

Department of Chemical Biology, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China

Received:2016-05-13 Revised:2016-07-25 Online:2016-11-26 Published:2016-08-10
Contact: Tel.: +86-010-82805956, E-mail: yxg@bjmu.edu.cn
Supported by:
This work was supported by National Natural Science Foundation of China (Grant No. 21171011 and 21671009).

Abstract

Abstract:

Insulin resistance is characterized as one of crucial pathological changes in type 2 diabetes mellitus (T2DM), and dyslipidaemia is frequently detected in T2DM. A variety of vanadium compounds have been studied as drug candidates for diabetes based on their insulin-like action. However, few studies focus on their antilipolytic effect. In the present study, we established an insulin-resistant model in 3T3-L1 adipocytes to mimic pathological conditions of T2DM according to a well-established method by the treatment of high concentrations of glucose and insulin, which was validated by oil red O staining and the decreased levels of phosphorylated Akt, AS160 and GSK3 after insulin treatment. The results demonstrated that bis(acetylacetonato)-oxidovanadium (IV) (VO(acac)₂) could inhibit isoproterenol-stimulated lipolysis through the reduction of the phosphorylated HSL and perilipin levels in both insulin-sensitive and insulin-resistant 3T3-L1 adipocytes. Moreover, although the levels of phosphorylated Akt induced by VO(acac)₂ were decreased, the rates of lipolytic inhibition were not significantly altered compared with those under insulin-sensitive condition, indicating that the anti-lipolytic effect of VO(acac)₂ might also function in an Akt-independent way in insulin-resistant adipocytes. Our work here help elucidate the anti-diabetic effects of vanadium compounds. It may not only shed light on the utility of vanadium-based compounds as potential anti-diabetic drugs but also serve as a useful screening model for new anti-diabetic drugs.

Key words: Bis(acetylacetonato)-oxidovanadium (IV), Lipolysis, Insulin-resistant 3T3-L1 adipocytes

CLC Number:

R977.15

Supporting:

Xia Hu, Jingcheng Liu, You Yu, Weixia Bian, Xiaogai Yang. Bis(acetylacetonato)-oxidovanadium(IV) inhibits isoproterenol-induced lipolysis in insulin-resistant 3T3-L1 adipocytes by reducing phosphorylation of perilipin and hormone-sensitive lipase[J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(11): 814-820.

References

[1] Krauss, R.M. Diabetes Care. 2004, 27, 1496-1504.
[2] Mooradian, A.D. Nat. Clin. Pract. Endocrin. Metab. 2009, 5, 150-159.
[3] Athyros, V.G.; Tziomalos K.; Karagiannis, A.; Mikhailidis, D.P. Open Cardiovas. Med. J. 2011, 5, 24.
[4] Boden, G. Diabetes. 1997, 46, 3-10.
[5] Boden, G.; Shulman, G. Eur. J. Clin. Invest. 2002, 32, 14-23.
[6] Heyliger, C.E.; Tahiliani, A.G.; McNeill, J.H. Science. 1985, 227, 1474-1477.
[7] Reul, B.A.; Amin, S.S.; Buchet, J.P.; Ongemba, L.N.; Crans, D.C.; Brichard, S.M. Br. J. Pharmacol. 1999, 126, 467-477.
[8] Ou, H.; Yan, L.; Mustafi, D.; Makinen, M.W.; Brady, M.J. J. Biol. Inorg. Chem. 2005, 10, 874-886.
[9] Kawabe, K.; Yoshikawa,Y.; Adachi, Y.; Sakurai, H. Life Sci. 2006, 78, 2860-2866.
[10] Li, J.; Elberg, G.; Sekar, N.; He, Z.; Shechter, Y. Endocrinology. 1997, 138, 2274-2279.
[11] Shechter, Y. Diabetes. 1990, 39, 1-5.
[12] Gao, L.; Niu Y.; Liu, W.; Xie, M.; Liu, X.; Chen, Z.; Li, L. Clin. Chim. Acta. 2008, 388, 89-94.
[13] Thompson, K.H.; Lichter, J.; LeBel, C.; Scaife, M.C.; McNeill, J.H.; Orvig, C. J. Inorg. Biochem. 2009, 103, 554-558.
[14] Li, J.; Elberg, G.; Sekar, N.; He, Z.B.; Shechter, Y. Endocrinology. 1997, 138, 2274-2279.
[15] Ling, H.Y.; Ou, H.S.; Feng, S.D.; Zhang, X.Y.; Tuo, Q.H.; Chen, L.X.; Zhu, B.Y.; Gao, Z.P.; Tang, C.K.; Yin, W.D.; Zhang, L.; Liao, D.F. Clin. Exp. Pharmacol. Physiol. 2009, 36, e32-39.
[16] Thomson, M.J.; Williams, M.G.; Frost, S.C. J. Biol. Chem. 1997, 272, 7759-7764.
[17] Ross, S.A.; Chen, X.; Hope H.R.; Sun, S.; McMahon, E.G.; Broschat, K.; Gulve, E.A. Biochem. Biophys. Res. Commun. 2000, 273, 1033-1041.
[18] Fauman, E.B.; Yuvaniyama, C.; Schubert H.L.; Stuckey, J.A.; Saper, M.A. J. Biol. Chem. 1996, 271, 18780-18788.
[19] Liu, J.C.; Yu, Y.; Wang, G.; Wang, K., Yang, X.G. Metallomics. 2013, 5, 813-820.

[20] Wang, Q.; Liu, T.T.; Fu, Y.; Wang, K.; Yang, X.G. J. Biol. Inorg. Chem. 2010, 15, 1087-1097.
[21] Choi, S.M.; Tucker, D.F.; Gross, D.N.; Easton, R.M.; DiPilato, L.M.; Dean, A.S.; Monks, B.R.; Birnbaum, M.J. Mol. Cell Biol. 2010, 30, 5009-5020.
[22] Hara-Chikuma, M.; Sohara, E.; Rai, T.; Ikawa, M.; Okabe, M.; Sasaki, S.; Uchida, S.; Verkman, A. J. Biol. Chem. 2005, 280, 15493-15496.
[23] Li, X.; Ge, H.; Weiszmann, J.; Hecht, R.; Li, Y.; Véniant, M.M.; Xu, J.; Wu, X.; Lindberg, R. FEBS Lett. 2009, 583, 3230-3234.
[24] Otto, T.C.; Lane, M.D. Crit. Rev. Biochem. Mol. Biol. 2005, 40, 229-242.
[25] Taniguchi, C.M.; Emanuelli, B.; Kahn, C.R. Nat. Rev. Mol. Cell Biol. 2006, 7, 85-96.
[26] Ahmadian, M.; Wang, Y.; Sul, H.S. Int. J. Biochem. Cell Biol. 2010, 42, 555-559.
[27] Anthonsen, M.W.; Ronnstrand, L.; Wernstedt, C.; Degerman, E.; Holm, C. J. Biol. Chem. 1998, 273, 215-221.
[28] Brasaemle, D.L. J. Lipid Res. 2007, 48, 2547-2559.
[29] Brasaemle, D.L.; Levin, D.M.; Adler-Wailes, D.C.; Londos, C. BBA-Mol. Cell. Biol. Lipids. 2000, 1483, 251-262.
[30] Jocken, J.W.; Blaak, E.E. Physiol. Behav. 2008, 94, 219-230.
[31] Carmen, G.Y.; Victor, S.M. Cell Signal. 2006, 18, 401-408.
[32] Pluskey, S.; Mahroof-Tahir, M.; Crans, D.C.; Lawrence, D.S. Biochem. J. 1997, 321, 333-339.
[33] Motoyashiki, T.; Morita, T.; Ueki, H. Biol. Pharm. Bull. 1996, 19, 1412-1416.
[34] Motoyashiki, T.; Miyake, M.; Yoshida, A.; Morita, T.; Ueki, H. Biol. Pharm. Bull. 1999, 22, 780-786.

Bis(acetylacetonato)-oxidovanadium(IV) inhibits isoproterenol-induced lipolysis in insulin-resistant 3T3-L1 adipocytes by reducing phosphorylation of perilipin and hormone-sensitive lipase

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 2

Recommended Articles

Metrics

Comments

[1]	Yi Li, Jingcheng Liu, You Yu, Weixia Bian, Xia Hu, Xiaogai Yang. Role of vanadyl acetylacetonate-induced elevation of reactive oxygen species in the regulation of lipolysis and glucose metabolism in 3T3L1 adipocytes [J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(11): 726-733.
[2]	Renbo Ding, Jiaolin Bao, Yiwei Cao, Chengwei He, Yitao Wang, Jianbo Wan. Panax notoginseng saponins protect against chronic ethanol-induced hepatic steatosis [J]. Journal of Chinese Pharmaceutical Sciences, 2014, 23(6): 361-368.